CJC-1295 + Ipamorelin: How the Growth Hormone Stack Actually Works
The most popular growth-hormone-stimulating peptide stack in clinical practice. Here's what each component does, why they're paired, and what to expect.
The CJC-1295 + Ipamorelin combination is the most-prescribed growth-hormone-stimulating peptide protocol in U.S. clinical practice. Understanding why it's a stack — rather than either drug alone — is the key to using it well.
CJC-1295: a GHRH analog
CJC-1295 is a synthetic analog of growth-hormone-releasing hormone (GHRH). It binds the GHRH receptor on the pituitary and signals "release GH." On its own, this produces a measurable rise in GH and IGF-1.
Ipamorelin: a selective ghrelin mimetic
Ipamorelin acts on a separate pituitary pathway — the GHSR (ghrelin) receptor. It also triggers GH release, but through a different mechanism. Unlike older ghrelin analogs, it does not significantly raise cortisol or prolactin, which is why it dominates modern protocols.
Why the stack works synergistically
Activating both the GHRH and the ghrelin pathways simultaneously produces a larger GH pulse than either alone — roughly additive effects, sometimes more. The biology is consistent across animal and human studies of GH secretagogue pairing.
Typical dosing
The conventional protocol is 100 mcg CJC-1295 (no DAC) + 100 mcg ipamorelin, administered subcutaneously at bedtime. The timing leverages your natural overnight GH pulse rather than fighting it. Most clinicians cycle the protocol — 5 days on, 2 off — to preserve receptor sensitivity.
What patients notice
Improved sleep quality is usually the first reported change (within 1–2 weeks), followed by faster recovery from training, modest body recomposition over 8–12 weeks, and skin and hair quality improvements. These effects are real but not dramatic — this is gentle, physiologic GH support, not exogenous HGH.
What it isn't
This stack is not synthetic human growth hormone (HGH). It stimulates your body's own GH production rather than replacing it, which means your natural feedback loops remain intact and the safety profile is materially different from exogenous HGH.
Sources & references
Peer-reviewed studies, clinical guidelines, and regulatory documents used to write this article.
- 1.Sigalos JT, Pastuszak AW. The Safety and Efficacy of Growth Hormone Secretagogues. Sex Med Rev. 2018;6:45-53.— Sexual Medicine Reviews, 2018.
- 2.Raun K et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139:552-561.— European Journal of Endocrinology, 1998.
- 3.Teichman SL et al. Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295. J Clin Endocrinol Metab. 2006;91:799-805.— Journal of Clinical Endocrinology and Metabolism, 2006.
How this article was written: Researched and drafted by the Valora Rx editorial team using current peer-reviewed literature and clinical practice guidelines from bodies including the Endocrine Society, AUA, NAMS, ACOG, and FDA. This article is informational and is not a substitute for individualized medical advice from your physician. Read our editorial standards →
